April 15 (Reuters) - Organovo Holdings said on Monday its experimental drug to treat a type of fatty liver disease helped significantly reduce liver fat in a mid-stage study. (Reporting by Mariam Sunny in Bengaluru)
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.04 USD | +4.00% | +0.97% | -6.31% |
1st Jan change | Capi. | |
---|---|---|
-6.31% | 11.39M | |
+2.64% | 42.75B | |
+47.70% | 41.61B | |
+12.25% | 41.34B | |
-8.83% | 26.59B | |
+7.86% | 25.49B | |
-22.53% | 18.12B | |
+30.96% | 12.24B | |
-1.62% | 11.76B | |
+9.44% | 11B |
- Stock Market
- Equities
- ONVO Stock
- News Organovo Holdings, Inc.
- Organovo's fatty liver disease drug meets main goal in mid-stage study